Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Mallinckrodt
US Army
Accenture
McKinsey
Julphar
Cipla
Harvard Business School
Chinese Patent Office
Baxter

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,981,889

« Back to Dashboard

Summary for Patent: 7,981,889
Title:Phthalazinone derivatives
Abstract: Compounds of the formula (I): ##STR00001## wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NR.sup.X or CR.sup.XR.sup.Y; if X.dbd.NR.sup.X then n is 1 or 2 and if X.dbd.CR.sup.XR.sup.Y then n is 1; R.sup.X is selected from the group consisting of H, optionally substituted C.sub.1-20 alkyl, C.sub.5-20 aryl, C.sub.3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; R.sup.Y is selected from H, hydroxy, amino; or R.sup.X and R.sup.Y may together form a spiro-C.sub.3-7 cycloalkyl or heterocyclyl group; R.sup.C1 and R.sup.C2 are both hydrogen, or when X is CR.sup.XR.sup.Y, R.sup.C1, R.sup.C2, R.sup.X and R.sup.Y, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R.sup.1 is selected from H and halo.
Inventor(s): Barr Martin; Niall Morrison (Cambridge, GB), Smith; Graeme Cameron (Cambridge, GB), Jackson; Stephen Philip (Cambridge, GB), Loh; Vincent Junior M (Horsham, GB), Cockcroft; Xiao-Ling Fan (Horsham, GB), Williams Matthews; Ian Timothy (Horsham, GB), Menear; Keith Allan (Horsham, GB), Kerrigan; Frank (Cornwall, GB), Ashworth; Alan (London, GB)
Assignee: Kudos Pharmaceuticals Limited (Cambridge, GB) Maybridge Limited (Cornwall, GB)
Application Number:12/109,260
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,981,889

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms LYNPARZA olaparib CAPSULE;ORAL 206162-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,981,889

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,912,187 Phthalazinone derivatives ➤ Subscribe
7,449,464 Phthalazinone derivatives ➤ Subscribe
7,662,818 Phthalazinone derivatives ➤ Subscribe
9,169,235 Phthalazinone derivatives ➤ Subscribe
8,143,241 DNA damage repair inhibitors for treatment of cancer ➤ Subscribe
8,071,579 DNA damage repair inhibitors for the treatment of cancer ➤ Subscribe
9,566,276 Phthalazinone derivatives ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,981,889

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 94209 ➤ Subscribe
Taiwan I338000 ➤ Subscribe
Taiwan 200530196 ➤ Subscribe
Taiwan I336694 ➤ Subscribe
Taiwan 200505871 ➤ Subscribe
Tunisia SN05212 ➤ Subscribe
Slovenia 1633724 ➤ Subscribe
Singapore 150548 ➤ Subscribe
Russian Federation 2010149166 ➤ Subscribe
Russian Federation 2413515 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Fish and Richardson
Mallinckrodt
McKesson
Johnson and Johnson
Fuji
Chinese Patent Office
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot